Ontology highlight
ABSTRACT: Background
We report on the safety and immunogenicity of V591, a measles vector-based SARS-CoV-2 vaccine candidate.Methods
In this multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial, healthy adults with no history of COVID-19 disease were assigned to intramuscular injection of V591 or placebo (4:1 ratio). In part 1, younger adults (18-55 years) received V591 median tissue culture infectious dose (TCID50)-levels of 1×105 or 1×106 or placebo, 56 days apart. In part 2, younger and older (>55 years) adults received a single dose of one of four (104/105/106/107) or one of two (105/106) V591 TCID50 levels, respectively, or placebo.Primary outco
SUBMITTER: Vanhoutte F
PROVIDER: S-EPMC8759950 | biostudies-literature | 2022 Jan
REPOSITORIES: biostudies-literature